METROSIL
2.3.2016 04:01:55 CET | Business Wire | Press release
Metrosil , the world leader in silicon carbide non-linear resistors (called varistors) today announced the launch of its new range of De-Excitation Units - the “Metrosil 8000 Series”, designed to protect large electrical generators. The all-new 8000 Series (protected by Registered Design) has been developed around an improved ergonomic structure, an industry first, providing not only protection for the varistor discs, but also simplifying the installation of the units. Another unique feature is the inclusion of a high energy test certificate with every 8000 Series unit, providing proof that the varistors perform as required. De-Excitation varistors protect electricity generating equipment (for example in hydropower and nuclear installations) from the damaging effects of powerful high energy surges.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160301006459/en/
8000 Series features include:
- Protective bar to prevent accidental disc damage
- Anti-tamper device to ensure unit integrity
- Ergonomic handles for easy carrying and installation
- Robust, easy-access connection points
- Range of standard footprints enables consistent installation
- Nameplate –permanently displays the unit’s specification details
- Each unit shipped with certification of high energy testing
- Clearly labelled with High Energy Test “Pass” badge
James O’Brien, Metrosil’s Product Group Director, commented “Metrosil constantly innovates and responds to customer feedback. With its new design, anti-tamper and ergonomic features, the 8000 Series is a more robust, long-lasting product. All Metrosil excitation products are tested to 100% of its specification – it’s part of what makes us unique in the industry, and we’re thrilled to launch another Metrosil first for the power generation industry.”
The Metrosil commercial team will be showing the 8000 Series at industry trade shows and also to individual utilities and power generation companies. To arrange a Metrosil 8000 Series visit, email requests should be sent to Ian Rowley, Metrosil’s Business Development Manager: ianrowley@mimaterials.com .
Ends
About Metrosil
Metrosil is the leading brand of high performance over-voltage protection devices for a wide range of power generation and transmission applications around the globe. It is a product of M&I Materials Limited in Manchester, UK. Since 1936, millions of Metrosil varistors have been sold throughout the world, used in flagship power projects including:
- Three Gorges Hydroelectric Dam, China
- La Grande, Canada
- Grand Coulee Dam, USA
- Itaipu, Brazil/Paraguay
About M&I Materials Limited
M&I Materials Limited is an international manufacturing company producing Specialist Materials for Industry and Science to customers located in more than sixty countries worldwide. www.mimaterials.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160301006459/en/
Contact:
M&I Materials Ltd
Ian Rowley, Metrosil Business Development
Manager
Tel: +44 (0) 161 864 5490
E-mail: ianrowley@mimaterials.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom